Palliative Care Coaching for Families With Rare Advanced Lung Diseases

Lung Diseases Clinical Trial

Official title:

Palliative Care Coaching for Family Caregivers & Patients With Rare Advanced Lung Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03813667
• Other study ID #: 1703528067
• Status: Completed
• Phase: N/A
• Start date: November 1, 2018
• Est. completion date: September 30, 2019

Study information

• Verified date: October 2019
• Source: West Virginia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

With one of the highest incidences of lung disease deaths in the nation, there is great need for home end-of-life palliative care in the rural, disadvantaged communities of West Virginia. The aims of this proposed study are to: (1) pilot test the nursing care intervention with patients and family members managing home supportive EOLPC for rare advanced lung disease and (2) collect research data to report in the NIH resubmission and future trials.

Description:

Nearly 15 million Americans and greater than 10% of West Virginia (WV) residents live with and eventually die from Rare and Advanced Lung Diseases (R-ALD), including pneumoconiosis (i.e., dust, asbestos), and idiopathic pulmonary fibrosis. Patients with R-ALD experience refractory breathlessness, depression, fatigue, and extreme worry about their family members and cost of health care. With one of the highest incidences of lung disease deaths in the nation, there is great need for home EOLPC in the rural, disadvantaged communities of WV. The proposed EOLPC intervention (FamPALcare) is based on R-ALD experts' input, national EOLPC guidelines, and the PI's published EOLPC studies with breathlessness in end-stage heart failure (HF) patients.

This project is well-aligned with the National Institutes of Health (NIH) priority specific to "Appalachian populations experiencing extreme inequities and poor access to healthcare" and the NIH PAR on palliative care for family caregivers and patients with advanced lung diseases. The PI's NIH application review, which received a positive score, stated that this project will have a high impact on improving palliative care for rural families managing lung disease and the project can be translated to other rural communities. This is an initial study of coaching home-based palliative R-ALD care in rural Appalachia. The NIH review stated using the PI's culturally sensitive approaches for R-ALD was novel for chronic lung disease. Also, addressing both family caregivers' and patients' needs was noted as innovative and increased the potential for future funding, as was the rigorous protocol for observing intervention fidelity.

This study uses a random control group comparison design to test the implementation of the FamPALcare intervention with R-ALD patients and their primary family caregiver. Specific aims are to: (1) pilot test the FamPALcare nursing care intervention with patients and family members managing home supportive EOLPC for R-ALD and (2) collect research data to report in the PI's NIH resubmission and future trials. The control patients receive standard care given through the WVU hospital and outpatient clinics, prescribed by the patient's pulmonologist, and recorded in the medical record. The FamPALcare intervention group receives all standard care plus 2 weeks of home EOLPC coaching by community nurses experienced in EOLPC. Data will be collected at baseline, month one, and month three from patients and caregivers independently. This pilot study provides testing of our research guides and procedures that will be described to enhance the NIH resubmission and will determine power needed for the future RCT design.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: September 30, 2019
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients diagnosed with R-ALD, and their primary family caregivers dyad.

• All participants must be alert and oriented.

• Be able to read and write in English.

Exclusion Criteria:

• Patients who have received or are on a waiting list for a lung transplant

• Patients diagnosed with another terminal illness.

Related Conditions & MeSH terms

• Lung Diseases
• Rare Non-Neoplastic Disorder

Intervention

Behavioral:
• Intervention FamPALcare
The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the "Conversation Ready" pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use "teach-back" processes to ensure that FamPALcare discussions are clear.

Locations

Country	Name	City	State
United States	West Virginia University Hospital	Morgantown	West Virginia

Sponsors (1)

Lead Sponsor	Collaborator
West Virginia University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	patient outcomes	The intervention group R-ALD patients will report lower scores on breathlessness scale compared to control group patients at 3 months.; Breathlessness is measured by Self-report shortness of breath scale (1 item, 0-10; 0-no shortness of breath, 10 = shortness of breath as bad as can be) (Gift, Narsavage, 1998	3 months
Secondary	family caregiver outcomes	The intervention group family caregivers will rate lower scores on Anxiety and Depression on PHQ-4 Scale compared to control group caregivers at 3 months.; Anxiety and Depression are measured by PHQ-4 Scale, 4-item Likert scale.	3 months
Secondary	patients' decision on EOLPC	The intervention group will report higher numbers of signed advance directives.; This outcome is measured by the presence of signed advance directives in the medical record. Various types of advance directives will be identified.	3 months
Secondary	Helpfulness of home R-ALD EOLPC intervention	Each patient and family member will rate the 11-item Likert Intervention on the Helpfulness scale at 3 months. Range 1-5, 1= strongly disagree/not helpful and 5 = strong agree/helpful.	3 months